These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 25620390)
1. Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients. Cariello PF; Kwak EJ; Abdel-Massih RC; Silveira FP Transpl Infect Dis; 2015 Feb; 17(1):111-8. PubMed ID: 25620390 [TBL] [Abstract][Full Text] [Related]
2. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin. Jarand J; Davis JP; Cowie RL; Field SK; Fisher DA Chest; 2016 May; 149(5):1285-93. PubMed ID: 26513209 [TBL] [Abstract][Full Text] [Related]
3. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Mehta RT Antimicrob Agents Chemother; 1996 Aug; 40(8):1893-902. PubMed ID: 8843300 [TBL] [Abstract][Full Text] [Related]
4. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Field SK; Cowie RL Chest; 2003 Oct; 124(4):1482-6. PubMed ID: 14555583 [TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy. Jo KW; Kim S; Lee JY; Lee SD; Kim WS; Kim DS; Shim TS J Infect Chemother; 2014 Oct; 20(10):602-6. PubMed ID: 24981714 [TBL] [Abstract][Full Text] [Related]
6. Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. Garrelts JC DICP; 1991 May; 25(5):525-31. PubMed ID: 2068838 [TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial. Zweijpfenning SMH; Aarnoutse R; Boeree MJ; Magis-Escurra C; Stemkens R; Geurts B; van Ingen J; Hoefsloot W Chest; 2024 May; 165(5):1082-1092. PubMed ID: 38040054 [TBL] [Abstract][Full Text] [Related]
8. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Doucette K; Fishman JA Clin Infect Dis; 2004 May; 38(10):1428-39. PubMed ID: 15156482 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo synergistic effect of isoniazid with streptomycin and clofazimine against Mycobacterium avium complex (MAC). Reddy MV; Srinivasan S; Gangadharam PR Tuber Lung Dis; 1994 Jun; 75(3):208-12. PubMed ID: 7919314 [TBL] [Abstract][Full Text] [Related]
10. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. Longworth SA; Vinnard C; Lee I; Sims KD; Barton TD; Blumberg EA Transpl Infect Dis; 2014 Feb; 16(1):76-83. PubMed ID: 24350627 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection. Kansal RG; Gomez-Flores R; Sinha I; Mehta RT Antimicrob Agents Chemother; 1997 Jan; 41(1):17-23. PubMed ID: 8980748 [TBL] [Abstract][Full Text] [Related]
12. In vitro, in vivo, and intracellular chemotherapeutic activity of B746, a clofazimine analogue against Mycobacterium avium complex. Gangadharam PR; Ashtekar D; O'Sullivan JF Tuber Lung Dis; 1992 Aug; 73(4):192-9. PubMed ID: 1477384 [TBL] [Abstract][Full Text] [Related]
13. Clinical features and outcomes of tuberculosis in solid organ transplant recipients. Bodro M; Sabé N; Santín M; Cruzado JM; Lladó L; González-Costello J; Carratalà J Transplant Proc; 2012 Nov; 44(9):2686-9. PubMed ID: 23146494 [TBL] [Abstract][Full Text] [Related]